3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
3
Phase 2
2
Phase NA
1
Phase 1/2
1
Status
Recruiting
3
Completed
2
Terminated
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
3
Sponsor
Cancer Type
Genitourinary
3
Conditions
Breast Neoplasms
129
Carcinoma, Non-Small-Cell Lung
101
Prostatic Neoplasms
62
Colorectal Neoplasms
49
Nasopharyngeal Carcinoma
46
Neoplasms
43
Multiple Myeloma
41
Stomach Neoplasms
34
Lung Neoplasms
32
Ovarian Neoplasms
31
Neoplasm Metastasis
31
Leukemia, Myeloid, Acute
31
Carcinoma, Hepatocellular
29
Squamous Cell Carcinoma of Head and Neck
27
Rectal Neoplasms
27
Triple Negative Breast Neoplasms
25
Recurrence
25
Pancreatic Neoplasms
25
Small Cell Lung Carcinoma
21
Esophageal Neoplasms
21
Brain Neoplasms
21
Uterine Cervical Neoplasms
20
Colonic Neoplasms
20
Lymphoma, Large B-Cell, Diffuse
18
Head and Neck Neoplasms
17
Urinary Bladder Neoplasms
16
Leukemia, Lymphocytic, Chronic, B-Cell
16
Esophageal Squamous Cell Carcinoma
16
Carcinoma, Renal Cell
16
Myasthenia Gravis
15
Interventions
Androgen Antagonists
2
fludrocortisone acetate
1
enzalutamide
1
darolutamide
1
Radiosurgery
1
Prednisone
1
Pluvicto
1
Lutetium-177
1
Lutetium
1
Hydrocortisone
1
Docetaxel
1
Dexamethasone
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Phase 3
×
Recruiting
×
Prostate Cancer Metastatic
×
Clear all
NCT06136624
2026-05-05
OMAHA-003
Merck Sharp & Dohme LLC
Phase 3
Recruiting
1,310 enrolled
NCT04916613
2026-04-28
GETUG-AFU 40
UNICANCER
Phase 3
Recruiting
300 enrolled
NCT06320067
2025-09-26
STAMPEDE2
University College, London
Phase 3
Recruiting
3,360 enrolled